Morgan Stanley removed the company from its 2026 top investment ideas list due to rising regulatory pressure and a challenging consumer environment. Arete Research downgraded the stock from Buy to Hold with a $130 price target. Freedom Capital Markets noted it is no longer a Top Pick at Morgan Stanley. Wall Street opinion is described as mixed, though some analysts still categorize it as an undervalued cyclical stock.